logo
California produce supplier is sued, accused of causing E. coli outbreak unreported by FDA

California produce supplier is sued, accused of causing E. coli outbreak unreported by FDA

Yahoo24-04-2025

Salinas-based produce supplier Taylor Fresh Foods is facing lawsuits from nine victims of a November E. coli outbreak that was not disclosed to the public.
The outbreak — which killed one person and sickened at least 88 more — was linked to romaine lettuce and spanned at least 15 states, including Missouri and Indiana.
Federal investigators traced the cases back to a single grower, but the Food and the Drug Administration didn't disclose the name.
Read more: E. coli hammers a California town, sending patients to ER and shutting down restaurants
The details of the investigation came to light only after several affected parties, including the parents of a 10-year-old victim earlier this month, filed lawsuits alleging Taylor Fresh Foods and Taylor Farms California — referred to as "Taylor Farms" in court documents — originated the "defective and unreasonably dangerous" food products that caused the E. coli outbreak.
Taylor Farms in a Thursday statement to The Times denied that it was the source of the E. coli outbreak and said it is "considering all legal action to defend itself."
"We perform extensive raw and finished product testing on all our product and there was no evidence of contamination," the supplier said, adding that its produce is processed using USDA-verified wash systems.
Read more: There are now 90 victims in McDonald's E. coli outbreak; lawsuits begin to roll in
In a federal lawsuit against Taylor Fresh Foods and Taylor Farms California filed last week, Indiana residents Amber and Chris George alleged that their then 9-year-old son Colton George became severely ill and was hospitalized after eating romaine lettuce allegedly supplied by the California producer.
He was later diagnosed with hemolytic uremic syndrome (HUS), a life-threatening kidney condition, from an E. coli strain that was confirmed by genetic testing to match other cases in the outbreak.
The boy's condition forced him to undergo dialysis for two weeks — including on his 10th birthday, the complaint said.
The Georges demanded that Taylor Farms pay their son's medical bills among other damages, including for "loss of enjoyment of life" and "emotional distress."
Read more: A wave of major listeria recalls shows food safety will 'never be perfect'
Taylor Farms' products were previously linked to a separate E. coli outbreak in October. The supplier voluntarily recalled the onion products at fault, and the FDA cautioned the public about the contaminated yellow onions, which were being served on McDonald's hamburgers.
This time, the FDA said "there were no public communications related to this outbreak" because the contaminated lettuce was no longer being sold when its distributor was identified, according to an internal report obtained by NBC.
The FDA also said in a statement to NBC that it names firms only "when there is enough evidence linking an outbreak to a firm and there is actionable advice for consumers, as long as naming the firm is not legally prohibited."
"By the time investigators had confirmed the likely source, the outbreak had already ended and there was no actionable advice for consumers," the agency said.
The Centers for Disease Control and Prevention wrote in a letter the previous month that the outbreak was over.
Representatives for the FDA and CDC did not respond to requests for comment.
Read more: As FDA probes source of national E. coli outbreak, California firm recalls onion products
Bill Marler, the attorney representing the nine victims suing Taylor Farms, said he uncovered extensive evidence pointing to the supplier as the source of the outbreak. Marler said he obtained invoices from a St. Louis caterer listing Taylor Farms as its seller.
"The whole thing could be very much cleared up if the FDA did what they normally do, which is name the entity when they have it nailed down to an entity, which they do," Marler said.
Read more: Avocados, salmon, strawberry yogurt: Which of these meets FDA's new definition of a "healthy" food?
Marler said he was particularly disturbed by the FDA's decision not to publicize this outbreak or its source because the specific strain of E. coli that caused it — E. coli O157:H7 — has been linked to several prior outbreaks.
"That tells you that there's some sort of systemic problem in the growing environment," the attorney said.
"If you kind of ignore it and say, 'Oh well, the outbreak is over, we don't have to say anything,'" he said, "what incentive is there for companies to stop growing there?"
Jerold Mande, an adjunct professor of nutrition at the Harvard T.H. Chan School of Public Health and a former senior advisor to the FDA commissioner, said that even if a contaminated product is out of circulation by the time its source is identified, consumers still have a right to know the contamination occurred.
"A company's record in the past is indicative of what people might expect in the future as well, and so consumers should have that information," Mande said, adding that what they do with that information is up to them.
Mande said that the FDA has not historically excelled at transparency, and he is concerned that recent cuts to the agency's communications staff will make matters worse.
"The current administration, which has emphasized over and over again about radical transparency, should certainly be doing more to let consumers know what's going on in these cases," he said.
Darin Detwiler, a food safety expert and associate teaching professor at Northeastern University's College of Professional Studies, said that it's crucial for not only consumers but also other companies to know when any contamination occurs.
Under the Food Safety Modernization Act, food facilities are required to have food safety plans outlining how they will combat any contamination risks or other food safety hazards. Detwiler said these plans typically include likelihood-severity models, which measure the likelihood of a hazard occurring with the severity of its potential consequences.
"If a company is supposed to be putting together a likelihood-severity plan, and they don't know that their competitors — their commodity, their industry — is having these problems, how are they supposed to adequately capture this idea of likelihood and severity and then act upon it?" Detwiler said.
Sign up for our Wide Shot newsletter to get the latest entertainment business news, analysis and insights.
This story originally appeared in Los Angeles Times.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Researchers issue urgent warning over spread of dangerous disease carried by snails: 'Leading to outbreaks in new locations'
Researchers issue urgent warning over spread of dangerous disease carried by snails: 'Leading to outbreaks in new locations'

Yahoo

time16 minutes ago

  • Yahoo

Researchers issue urgent warning over spread of dangerous disease carried by snails: 'Leading to outbreaks in new locations'

Harmful parasites carried by snails may be spreading, in part due to human-caused climate change, according to reporting from The Telegraph in May. Marginalized populations, including women and girls, may suffer disproportionately from increased prevalence. Schistosomiasis is a parasitic infection caused by snail-carried worms. Infection typically starts with making contact with the worms in freshwater, such as in a canal, river, or pond. Person-to-person transmission can continue when urine or feces containing the parasite's eggs contaminates a water source. Symptoms — including fever, chills, coughing, and aches — can manifest within a couple of months, per the Centers for Disease Control and Prevention. Chronic infections can lead to anemia, bloody stools, urinary problems, organ damage, and more. Historically, 90% of the schistosomiasis cases requiring treatment have been located in Africa, but infections have also been documented in Asia, the Americas, and the Middle East. While the London-based outlet has reported more recent spreading in parts of Europe may be largely tourism- and migration-driven, researcher Bonnie Webster also told the publication that transmissions may emerge in further locations due to shifting weather patterns. Rising global temperatures are driving more frequent and more intense flooding events, causing snails to appear in new wet settings and increasing water contamination. "Climate change will likely cause dramatic changes in transmission which need to be understood," Webster, who studies the disease at London's Natural History Museum, told The Telegraph. "Some areas will become drier and other areas will become flooded, creating new water bodies. This will lead to snails changing where they can be found and cause the prevalence of schistosomiasis to increase and spread, leading to outbreaks in new locations." Communities in low- and middle-income countries lacking sufficient sanitation infrastructure are already disproportionately impacted by this serious issue, and women and girls are additionally vulnerable to its effects. All people can become infected by these parasites, but one manifestation of the disease — female genital schistosomiasis, or FGS — can cause sexual, reproductive, and other health concerns for women and girls. Gendered labor dynamics can make this group additionally susceptible to infection through activities like washing laundry in contaminated water. Unlimit Health says that around 56 million women and girls in sub-Saharan Africa are infected with FGS, which can go undiagnosed and, especially when misdiagnosed as a sexually transmitted infection or otherwise left untreated, can lead to bleeding, pelvic pain, ulcers, miscarriage, and infertility. It may also contribute to increased risks of HIV and cervical cancer. Overall, schistosomiasis impacts hundreds of millions of people each year, resulting in up to 20,000 deaths annually, according to The Telegraph. Unfortunately, as Webster said, "Once one snail is infected, they can infect a whole population of humans." Do you worry about getting diseases from bug bites? Absolutely Only when I'm camping or hiking Not really Never Click your choice to see results and speak your mind. While treatments exist, potential drug resistance and current medical shortages could hamper attempts to curtail infections. Experts relayed to The Telegraph that recent substantial cuts to the United States Agency for International Development may also stymie research and response efforts for neglected tropical diseases like schistosomiasis. NTDs disproportionately impact marginalized populations. The World Health Organization says they affect over 1 billion people globally and that NTDs are "often related to environmental conditions." Of course, because of travel and climate change, many such infections may spread to more communities and farther regions. The CDC notes that prevention includes clean-up of contaminated areas, implementation of sanitation systems, and avoiding swimming, wading, and washing in unsafe water. A number of these measures require funding. Staying updated about how human-caused climate change can impact health and well-being everywhere can be key to organizing effective responses to rising global temperatures. Especially together in groups, friends and neighbors can make a difference by exploring these issues, raising awareness, supporting pro-environment policies, and taking on climate-conscious shifts at home to help address the extreme weather that imperils billions worldwide. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.

Breakthrough procedure helps prevent amputations for Sacramento area patients
Breakthrough procedure helps prevent amputations for Sacramento area patients

Yahoo

timean hour ago

  • Yahoo

Breakthrough procedure helps prevent amputations for Sacramento area patients

( — A breakthrough surgery helping save limbs and lives took place in Sacramento on Wednesday morning. The procedure aims to treat people suffering from Peripheral Artery Disease. PAD is a serious and rarely-treated circulatory condition that restricts blood flow to the limbs due to narrowed blood vessels. It kills more people than breast, colon, and prostate cancer combined. 'Plaque that builds up in these arteries causes not only hardening of the arteries but also plaque in these blood vessels,' said Dr. Inder Singh, an interventional cardiovascular specialist at TLC Vascular. When blood can't flow properly, minor wounds can become dangerous. They can lead to infection and, in some cases, amputation. Michaels Distributing Center in San Joaquin County set to close, affecting over 200 jobs 'If they get an injury or they get a wound or they get a scratch, those will not heal because they don't have enough, adequate perfusion to heal those wounds,' Dr. Singh said. Helping to change patient outcomes, Dr. Singh is now performing a first-of-its-kind procedure using a newly FDA-cleared removable stent called SPUR. 'The idea with it is that basically that kind of treatment that deep penetrates into the tissue and treats it, it will prevent future closure or at least prolong the time from when the blood vessels close,' said Dr. Singh. 'Enabling the patients to be able to heal their wounds, which is really the main outcome we're looking for.' is the first in the Sacramento area to use SPUR, designed specifically for the small, fragile arteries below the knee. Unlike a traditional stent, the spur temporarily holds the vessel open and then is removed, leaving nothing behind. Charges filed against former Cal Fire employee in child pornography case 'We can see somebody on an outpatient basis one day and actually fix a problem rather than put a band-aid on, you know, the incorrect problem,' said Shelby Adney, a nurse practitioner at TLC Vascular. It's an innovative procedure now preventing amputations, healing wounds, and maintaining patients' normal lives. 'Once you can preserve that and heal their wounds… they get their life back,' Dr. Singh said. 'They're ambulatory. They can spend time with their family. You can do a lot of things that most people expect to do.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

Yahoo

time2 hours ago

  • Yahoo

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD). In the first week of June, Mesoblast held a Type B meeting with FDA under its Regenerative Medicines Advanced Therapy (RMAT) designation for REVASCOR to discuss components of a potential filing for a Biologics License Application (BLA). There was general alignment on items regarding chemistry, manufacturing & controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval. The Company will await the final minutes from FDA in order to provide detailed feedback and timelines for potential filing. In early July, Mesoblast has an upcoming meeting with FDA to discuss a pivotal trial of Ryoncil® in adults with SR-aGvHD. This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN), the objective being to extend the product's label from children to adults with SR-aGvHD. Ryoncil® is the first and only mesenchymal stromal cell product approved by the FDA for any indication. Ryoncil® became commercially available for purchase in the United States on March 28, 2025, within one quarter of receiving FDA approval to treat children with SR-aGvHD. More than 20 transplant centers will have been onboarded by the end of the quarter, exceeding the company's expectations at product launch. Mesoblast has continued to expand coverage for Ryoncil® to over 220 million US lives insured by commercial and government payers. To date, 37 of the 51 States provide fee-for-service Medicaid coverage for Ryoncil® through Orphan Drug Lists or medical exception / prior authorization (PA) process. The remainder will come online July 1, 2025, with mandatory coverage for all 24 million lives. 'We are very pleased with the momentum of interactions with FDA on both our cardiac and GvHD programs,' said Mesoblast Chief Executive Dr. Silviu Itescu. 'We are also encouraged by the strength of the of the Ryoncil® commercial launch, the rate of hospital onboarding, physician adoption, and payor coverage exceeding our expectations in the ten weeks since commercial launch. We will be providing an update on sales of Ryoncil® in our quarterly activities report at the end of next month.' About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast's RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets. About Mesoblast manufacturing: The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see LinkedIn: Mesoblast Limited and X: @Mesoblast Forward-Looking StatementsThis press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mesoblast's research and development programs; Mesoblast's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast's ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast's RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast's product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast's ability to enter into and maintain established strategic collaborations; Mesoblast's ability to establish and maintain intellectual property on its product candidates and Mesoblast's ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast's expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast's financial performance; developments relating to Mesoblast's competitors and industry; and the pricing and reimbursement of Mesoblast's product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact:Paul Hughes T: +61 3 9639 6036 Allison Worldwide Emma Neal T: +1 603 545 4843 E: BlueDot Media Steve Dabkowski T: +61 419 880 486 E: steve@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store